Paul Waako
Paul Waako has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Kigen
Department of Pharmacology and Toxicology, School of Medicine, Moi University
3 shared publications - Godfrey S. Bbosa
Department of Pharmacology and Therapeutics, Makerere University College of Health Sciences, Kampala, Uganda
3 shared publications - Naftali Busakhala
Department of Pharmacology and Toxicology, School of Medicine, Moi University, Eldoret P.O. Box 4606-30100, Kenya
3 shared publications - Patrick. J. Loehrer
Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN
3 shared publications - Jennifer Morgan
Indiana University Simon Cancer Center, 535 Barnhill Dr., RT 455, Indianapolis, IN 46202-5289, USA
2 shared publications - Agnes Namaganda
Department of Physiology, Makerere University, College of Health Sciences, Kampala, Uganda
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2614
Challenges and Opportunities for Kaposi Sarcoma Clinical Trials in Sub-Saharan Africa: A Review
Kaposi sarcoma is a vascular tumor that remains a significant global public health challenge, with approximately 70% of cases occurring in sub-Saharan Africa (SSA) where Human Immunodeficiency Virus (HIV) and Human Herpesvirus 8 (HHV-8) are highly prevalent. Furthermore, relatively few clinical trials have been conducted in SSA, potentially delaying the development of more effective interventions for this cancer. This review evaluated completed prospective clinical trials for the treatment of HIV-associated Kaposi sarcoma (KS) conducted in sub-Saharan Africa (SSA) and highlighted the complementary role of investigator-initiated clinical trials in drug development. We searched the internet and medical databases using relevant key terms. We identified 171 indexed HIV-KS clinical trials worldwide and extracted seven that were conducted in SSA between 1984 and July 2022. The first trial took place in Zimbabwe and was published in 2005. The second and third trials were conducted in South Africa and published in 2008 and 2012, respectively. The fourth and sixth trials were done in Kenya, Uganda, South Africa, Zimbabwe, and Brazil and were published in 2018 and 2020. The fifth was an investigator-initiated trial (IIT) done in Kenya and published between 2018 and 2019. The sixth trial featured the largest sample size and the most diverse study population. The seventh evaluated the effectiveness of locally sourced compression bandages for HIV-KS leg lymphedema in Kenya and was published in 2022. The number of clinical trials for interventions to treat HIV-KS in SSA remains disproportionate to the high burden of the disease in the region. Highlighting these research gaps may stimulate interest in studies aimed at finding a cure for HIV-KS in sub-Saharan Africa.
- 12 November 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (11) , 2614
Open AccessChallenges and Opportunities for Kaposi Sarcoma Clinical Trials in Sub-Saharan Africa: A Review
Kaposi sarcoma is a vascular tumor that remains a significant global public health challenge, with approximately 70% of cases occurring in sub-Saharan Africa (SSA) where Human Immunodeficiency Virus (HIV) and Human Herpesvirus 8 (HHV-8) are highly prevalent. Furthermore, relatively few clinical trials have been conducted in SSA, potentially delaying the development of more effective interventions for this cancer. This review evaluated completed prospective clinical trials for the treatment of HIV-associated Kaposi sarcoma (KS) conducted in sub-Saharan Africa (SSA) and highlighted the complementary role of investigator-initiated clinical trials in drug development. We searched the internet and medical databases using relevant key terms. We identified 171 indexed HIV-KS clinical trials worldwide and extracted seven that were conducted in SSA between 1984 and July 2022. The first trial took place in Zimbabwe and was published in 2005. The second and third trials were conducted in South Africa and published in 2008 and 2012, respectively. The fourth and sixth trials were done in Kenya, Uganda, South Africa, Zimbabwe, and Brazil and were published in 2018 and 2020. The fifth was an investigator-initiated trial (IIT) done in Kenya and published between 2018 and 2019. The sixth trial featured the largest sample size and the most diverse study population. The seventh evaluated the effectiveness of locally sourced compression bandages for HIV-KS leg lymphedema in Kenya and was published in 2022. The number of clinical trials for interventions to treat HIV-KS in SSA remains disproportionate to the high burden of the disease in the region. Highlighting these research gaps may stimulate interest in studies aimed at finding a cure for HIV-KS in sub-Saharan Africa.
- Open Access
- 20 October 2026
- Published by MDPI AG in Preprints.org
Challenges and Opportunities for Kaposi Sarcoma Clinical Trials in Sub-Saharan Africa: A Review
Kaposi sarcoma is a vascular tumor that remains a significant global public health challenge, with approximately 70% of cases occurring in sub-Saharan Africa (SSA), where Human Immunodeficiency Virus (HIV) and Human Herpesvirus 8 (HHV-8) are highly prevalent. Furthermore, relatively few clinical trials have been conducted in SSA, potentially delaying the development of more effective interventions for this cancer. This review evaluated completed prospective clinical trials for the treatment of HIV-associated Kaposi sarcoma (KS) conducted in sub-Saharan Africa (SSA) and highlighted the complementary role of investigator-initiated clinical trials in drug development. We searched the internet and medical databases using relevant key terms. We identified 171 indexed HIV-KS clinical trials worldwide and extracted seven that were conducted in SSA between 1984 and July 2022. The first trial took place in Zimbabwe and was published in 2005. The second and third trials were conducted in South Africa and published in 2008 and 2012, respectively. The fourth and sixth trials were done in Kenya, Uganda, South Africa, Zimbabwe, and Brazil, and were published in 2018 and 2020. The fifth was an investigator-initiated trial (IIT) done in Kenya and published in 2018 and 2019. The sixth trial featured the largest sample size and the most diverse study population. The seventh evaluated the effectiveness of locally sourced compression bandages for HIV-KS leg lymphedema in Kenya and was published in 2022. The number of clinical trials for interventions to treat HIV-KS in SSA remains disproportionate to the high burden of disease in the region. Highlighting research gaps may stimulate interest in studies aimed at finding a cure for HIV-KS in sub-Saharan Africa.
- 20 October 2026
- Published by MDPI AG in Preprints.org
Open AccessChallenges and Opportunities for Kaposi Sarcoma Clinical Trials in Sub-Saharan Africa: A Review
Kaposi sarcoma is a vascular tumor that remains a significant global public health challenge, with approximately 70% of cases occurring in sub-Saharan Africa (SSA), where Human Immunodeficiency Virus (HIV) and Human Herpesvirus 8 (HHV-8) are highly prevalent. Furthermore, relatively few clinical trials have been conducted in SSA, potentially delaying the development of more effective interventions for this cancer. This review evaluated completed prospective clinical trials for the treatment of HIV-associated Kaposi sarcoma (KS) conducted in sub-Saharan Africa (SSA) and highlighted the complementary role of investigator-initiated clinical trials in drug development. We searched the internet and medical databases using relevant key terms. We identified 171 indexed HIV-KS clinical trials worldwide and extracted seven that were conducted in SSA between 1984 and July 2022. The first trial took place in Zimbabwe and was published in 2005. The second and third trials were conducted in South Africa and published in 2008 and 2012, respectively. The fourth and sixth trials were done in Kenya, Uganda, South Africa, Zimbabwe, and Brazil, and were published in 2018 and 2020. The fifth was an investigator-initiated trial (IIT) done in Kenya and published in 2018 and 2019. The sixth trial featured the largest sample size and the most diverse study population. The seventh evaluated the effectiveness of locally sourced compression bandages for HIV-KS leg lymphedema in Kenya and was published in 2022. The number of clinical trials for interventions to treat HIV-KS in SSA remains disproportionate to the high burden of disease in the region. Highlighting research gaps may stimulate interest in studies aimed at finding a cure for HIV-KS in sub-Saharan Africa.
- Top Cited PapersOpen Access
- 10 January 2026
- Published by Springer Nature in Reproductive Health
- Vol. 23 (1)
Catching babies, carrying traditions: the voices and practices of traditional birth attendants in Mayuge District, East central Uganda
Background: Traditional Birth Attendants (TBAs) continue to support maternal and newborn care in rural Uganda, particularly where access to formal health facilities is limited. Their roles are deeply embedded in local culture and community trust, yet national policies provide inconsistent guidance on their engagement within the formal health system. Objective: To explore the evolution, experiences, practices, challenges, and perceived support needs of TBAs in Mayuge District, and examine their interaction with formal health structures. Methods: A qualitative narrative study was conducted with 15 purposively selected TBAs from all sub-counties of Mayuge District. In-depth interviews lasting 60 to 90 min were held at participants’ homes or workplaces. Participants described and demonstrated their maternal care practices. Audio recordings were transcribed, translated, and analyzed thematically. Results: Seven key themes emerged from the study: (1) Historical Developments and Evolution of TBAs, highlighting diverse pathways into practice such as apprenticeship, family mentorship, formal Ministry of Health training, and community programs; (2) Practices, Methods, and Approaches, detailing TBAs’ provision of antenatal, delivery, and postnatal care, and management of maternal and newborn complications using both traditional and modern methods including newborn resuscitation; (3) Infection Prevention and Control, revealing variable use of personal protective equipment and inconsistent waste disposal practices constrained by limited resources; (4) Maternal and Perinatal Death Surveillance and Response (MPDSR) Process, illustrating TBAs’ limited participation in formal death notifications and reviews; (5) Referral Process, highlighting complex referral behaviors involving health facilities, fellow TBAs, and traditional healers; (6) Socio-Cultural Influences on TBA Services, encompassing the impact of poverty, gender roles, community trust, and cultural norms; and (7) Challenges in Providing Safe and Effective Care, including barriers such as negative attitudes from health workers, transport difficulties, competition, and lack of formal support. Conclusion: TBAs in Mayuge District play a vital role in culturally grounded maternal care but face numerous challenges due to limited formal integration and support. Strategies are needed to strengthen collaboration, provide targeted training, and clarify policy to improve maternal and newborn health outcomes in underserved areas.
- 10 January 2026
- Published by Springer Nature in Reproductive Health
- Vol. 23 (1)
Top Cited PapersOpen AccessCatching babies, carrying traditions: the voices and practices of traditional birth attendants in Mayuge District, East central Uganda
Background: Traditional Birth Attendants (TBAs) continue to support maternal and newborn care in rural Uganda, particularly where access to formal health facilities is limited. Their roles are deeply embedded in local culture and community trust, yet national policies provide inconsistent guidance on their engagement within the formal health system. Objective: To explore the evolution, experiences, practices, challenges, and perceived support needs of TBAs in Mayuge District, and examine their interaction with formal health structures. Methods: A qualitative narrative study was conducted with 15 purposively selected TBAs from all sub-counties of Mayuge District. In-depth interviews lasting 60 to 90 min were held at participants’ homes or workplaces. Participants described and demonstrated their maternal care practices. Audio recordings were transcribed, translated, and analyzed thematically. Results: Seven key themes emerged from the study: (1) Historical Developments and Evolution of TBAs, highlighting diverse pathways into practice such as apprenticeship, family mentorship, formal Ministry of Health training, and community programs; (2) Practices, Methods, and Approaches, detailing TBAs’ provision of antenatal, delivery, and postnatal care, and management of maternal and newborn complications using both traditional and modern methods including newborn resuscitation; (3) Infection Prevention and Control, revealing variable use of personal protective equipment and inconsistent waste disposal practices constrained by limited resources; (4) Maternal and Perinatal Death Surveillance and Response (MPDSR) Process, illustrating TBAs’ limited participation in formal death notifications and reviews; (5) Referral Process, highlighting complex referral behaviors involving health facilities, fellow TBAs, and traditional healers; (6) Socio-Cultural Influences on TBA Services, encompassing the impact of poverty, gender roles, community trust, and cultural norms; and (7) Challenges in Providing Safe and Effective Care, including barriers such as negative attitudes from health workers, transport difficulties, competition, and lack of formal support. Conclusion: TBAs in Mayuge District play a vital role in culturally grounded maternal care but face numerous challenges due to limited formal integration and support. Strategies are needed to strengthen collaboration, provide targeted training, and clarify policy to improve maternal and newborn health outcomes in underserved areas.
- Open Access
- 10 September 2019
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 14 (1) , 1-8
Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya
Background: AIDS-related Kaposi sarcoma (AIDS-KS), a common malignancy in Kenya is associated with high morbidity and mortality. AIDS-KS is treated using bleomycin and vincristine (BV) plus or minus doxorubicin in most low resource settings, with response rates ranging from 24.8 to 87%. Survival in low resource settings has not been well documented. We report the three-year survival in a cohort of seventy patients referred to Moi Teaching and Referral Hospital (MTRH). Methods: Study participants are part of a randomized phase IIA trial on the use of gemcitabine compared to bleomycin plus vincristine for the treatment of Kaposi sarcoma after combination antiretroviral therapy (cART) in Western Kenya. All patients were followed for three years in MTRH. Survival was determined by three monthly physical examination and analysed using Kaplan-Meier method, while possible determinants of survival such as baseline characteristics, type of chemotherapy, initial CD4 counts, age at enrolment, gender and early response to chemotherapy were analysed using univariate and multivariate Cox regression. Results: Participants were aged between 19 and 70 years with 56% being male. The median CD4 count was 224 cells/μl, median duration of HIV diagnosis was 12.0 months and median duration of KS lesions after histology diagnosis before initiating chemotherapy was 4.8 weeks. At three years, 60 (85.7%) patients were alive. Six of those who died were under treatment with BV while four with gemcitabine. There was no difference in the probability of survival between the patients on either treatment arm (HR = 0.573 [95% C. I 0.143, 2.292; p = 0.4311]). Additionally, the hazard ratio (HR) for response after six weeks, age at enrolment and gender indicated that they were not significant determinants of survival. Patients with normal CD4 cell counts (> = 500/μl), had a HR of 0.401(0.05,3.23; p = 0.391), suggesting better survival. Conclusions: Patients with AIDS-KS treated with combined antiretroviral drugs had excellent three-year survival regardless of whether they were treated with BV or gemcitabine as first line therapy. An initial CD4 cell count of > = 500/μl appeared to improve survival while gender, age and early response to chemotherapy were not predictors of survival after three years. Trial registration: Number PACTR201510001.
- 10 September 2019
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 14 (1) , 1-8
Open AccessThree year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital, Kenya
Background: AIDS-related Kaposi sarcoma (AIDS-KS), a common malignancy in Kenya is associated with high morbidity and mortality. AIDS-KS is treated using bleomycin and vincristine (BV) plus or minus doxorubicin in most low resource settings, with response rates ranging from 24.8 to 87%. Survival in low resource settings has not been well documented. We report the three-year survival in a cohort of seventy patients referred to Moi Teaching and Referral Hospital (MTRH). Methods: Study participants are part of a randomized phase IIA trial on the use of gemcitabine compared to bleomycin plus vincristine for the treatment of Kaposi sarcoma after combination antiretroviral therapy (cART) in Western Kenya. All patients were followed for three years in MTRH. Survival was determined by three monthly physical examination and analysed using Kaplan-Meier method, while possible determinants of survival such as baseline characteristics, type of chemotherapy, initial CD4 counts, age at enrolment, gender and early response to chemotherapy were analysed using univariate and multivariate Cox regression. Results: Participants were aged between 19 and 70 years with 56% being male. The median CD4 count was 224 cells/μl, median duration of HIV diagnosis was 12.0 months and median duration of KS lesions after histology diagnosis before initiating chemotherapy was 4.8 weeks. At three years, 60 (85.7%) patients were alive. Six of those who died were under treatment with BV while four with gemcitabine. There was no difference in the probability of survival between the patients on either treatment arm (HR = 0.573 [95% C. I 0.143, 2.292; p = 0.4311]). Additionally, the hazard ratio (HR) for response after six weeks, age at enrolment and gender indicated that they were not significant determinants of survival. Patients with normal CD4 cell counts (> = 500/μl), had a HR of 0.401(0.05,3.23; p = 0.391), suggesting better survival. Conclusions: Patients with AIDS-KS treated with combined antiretroviral drugs had excellent three-year survival regardless of whether they were treated with BV or gemcitabine as first line therapy. An initial CD4 cell count of > = 500/μl appeared to improve survival while gender, age and early response to chemotherapy were not predictors of survival after three years. Trial registration: Number PACTR201510001.
- Open Access
- 25 August 2015
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 2 (3) , 273-287
Medication Error Disclosure and Attitudes to Reporting by Healthcare Professionals in a Sub-Saharan African Setting: A Survey in Uganda
Medication errors (MEs) are largely under-reported, which undermines quality improvement and medication risk management in healthcare.
- 25 August 2015
- Published by Springer Nature in Drugs - Real World Outcomes
- Vol. 2 (3) , 273-287
Open AccessMedication Error Disclosure and Attitudes to Reporting by Healthcare Professionals in a Sub-Saharan African Setting: A Survey in Uganda
Medication errors (MEs) are largely under-reported, which undermines quality improvement and medication risk management in healthcare.
- Open Access
- 26 June 2014
- Published by Springer Nature in BMC Public Health
- Vol. 14 (1) , 650
Factors predicting home storage of medicines in Northern Uganda
Medicines are kept in households Worldwide for first aid, treatment of chronic or acute disease conditions. This promotes inappropriate use of medicines and hence the associated risks. The study explored the factors which predict availability and utilization of medicines in households of Northern Uganda.
- 26 June 2014
- Published by Springer Nature in BMC Public Health
- Vol. 14 (1) , 650
Open AccessFactors predicting home storage of medicines in Northern Uganda
Medicines are kept in households Worldwide for first aid, treatment of chronic or acute disease conditions. This promotes inappropriate use of medicines and hence the associated risks. The study explored the factors which predict availability and utilization of medicines in households of Northern Uganda.